Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Metformin is used as a first‑line drug for the treatment of type 2 diabetes; however, drug repositioning studies have revealed its antitumor effects, mainly mediated through AMP‑activated protein kinase (AMPK) activation and AKT/mammalian target of rapamycin (mTOR) pathway inhibition in various types of cancer, including drug‑resistant cancer cells.
|
30816444 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Acquired platelet dysfunction and overproduction of platelet cyclic AMP in two patients with myeloid malignancies.
|
31240986 |
2019 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
GEM-induced metabolic reprogramming also activates AMP-activated protein kinase (AMPK), which promotes glycolytic flux and cancer stemness.
|
31508487 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclic AMP response element-binding protein (CREBBP) bromodomain has emerged as a hot target for cancer therapy.
|
30499778 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Aminopeptidase M (AMP) inhibition is of interest for several diseases, such as highly vascularized cancer types.
|
31795383 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Determination of the crystal structure of AMP-activated protein kinase (AMPK) is fundamental to understanding its biological function and role in a number of diseases related to energy metabolism including type 2 diabetes, obesity, and cancer.
|
29480465 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Many genotoxic cancer treatments activate AMP-activated protein kinase (AMPK), but the mechanisms of AMPK activation in response to DNA damage, and its downstream consequences, have been unclear.
|
29133590 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AMP-activated kinase (AMPK) is a major regulator of energy metabolism and a promising target for development of new treatments for type 2 diabetes and cancer.
|
30230919 |
2018 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Loss-of-function mutations of cyclic-AMP response element binding protein, binding protein (CREBBP) are prevalent in lymphoid malignancies.
|
28825697 |
2017 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here we provide an overview of the possible mechanisms modulating mitochondrial energy production and homeostasis in the intriguing scenario of neoplastic cells, focusing on the double-edged role of 5'-AMP activated protein kinase in cancer metabolism.
|
28213331 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gastric cancer (GC) is a common and lethal malignancy, and AMP-activated protein kinase-related kinase 5 (ARK5) has been discovered to promote cancer metastasis in certain types of cancer.
|
28662499 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Effect of Methanolic Extract of Dandelion Roots on Cancer Cell Lines and AMP-Activated Protein Kinase Pathway.
|
29234282 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Regulation of Cancer Cell Responsiveness to Ionizing Radiation Treatment by Cyclic AMP Response Element Binding Nuclear Transcription Factor.
|
28529924 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer.
|
29084986 |
2017 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Metformin Promotes AMP-activated Protein Kinase-independent Suppression of ΔNp63α Protein Expression and Inhibits Cancer Cell Viability.
|
28193839 |
2017 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LKB1 phosphorylates and activates AMP-activated protein kinase (AMPK), which negatively regulates cancer cell proliferation and metabolism.
|
26398719 |
2015 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here we demonstrate that MnSOD upregulation in cancer cells establishes a steady flow of H2O2 originating from mitochondria that sustains AMP-activated kinase (AMPK) activation and the metabolic shift to glycolysis.
|
25651975 |
2015 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cervical cancer is one of the most common gynecological malignancies worldwide, and its association with the AMP-activated protein kinase (AMPK) is still unknown.
|
26337566 |
2015 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NAALADL2 was also found to regulate levels of Ser133 phosphorylated C-AMP-binding protein (CREB), a master regulator of a number of cellular processes involved in cancer development and progression.
|
24240687 |
2014 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among the enzyme cascade, CD73, which catelyzes AMP breakdown to adenosine, has been found to be overexpressed in many types of cancer.
|
25126561 |
2014 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The oncoprotein E7 from human papillomavirus (HPV) strains that confer high cancer risk mediates cell transformation by deregulating host cellular processes and activating viral gene expression through recruitment of cellular proteins such as the retinoblastoma protein (pRb) and the cyclic-AMP response element binding binding protein (CBP) and its paralog p300.
|
25451029 |
2014 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Activation of AMP-activated protein kinase (AMPK) was required for bortezomib-induced autophagy induction in PANC-1 and HT-29 cells, and AMPK inhibition by its inhibitor compound C (CC) or RNAi-depletion suppressed bortezomib-induced autophagy, while dramatically enhancing cancer cell apoptosis/cytotoxicity.
|
24842158 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AMP-activated protein kinase (AMPK) has recently been considered as a potential target for cancer therapy.
|
22897928 |
2012 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Up-regulation of AMP-activated protein kinase in cancer cell lines is mediated through c-Src activation.
|
21245141 |
2011 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the recent past it has been identified that various N(10)-substituted acridones can reverse the multidrug resistance (MDR) in cancer by selectively inhibiting the multidrug resistance associated protein (MRP) and calmodulin dependent cyclic AMP phosphodiesterase.
|
19442050 |
2009 |